Recent studies of the intracellular signaling pathway initiated by ligands of the transforming growth factor β β (TGFβ β) family have provided new insights into how the receptors for such ligands phosphorylate their substrates -the Smads -and how signaling specificity is achieved.
Three recent studies have expanded our understanding of different aspects of TGFβ signaling. First, the crystal structure has been determined of part of one of the two subunits that make up the TGFβ receptor [4] , allowing a detailed examination of the transmembrane-signal transduction mechanism. Second, a protein that acts as an adaptor between the receptor and the Smads has been identified, providing new insights into the cytoplasmic events leading to Smad activation [5] . And third, the examination of the developmental roles of the C. elegans type I receptor, Sma-6, has provided in vivo genetic evidence that different type I receptors can interact with a single type II receptor [6] .
Structure of a type I receptor kinase domain
TGFβ signals are transduced across the plasma membrane by two related serine/threonine kinases, known as type I and type II receptors. In animals, this receptor family appears to be unique -all other transmembrane receptor kinases that have been identified phosphorylate tyrosine residues. One might therefore expect this pathway to function differently from their tyrosine kinase cousins and use unique components, and use of the Smad proteins mentioned above is one example of this.
Another novel feature of TGFβ signaling is the so-called GS domain of the type I receptor. This domain is phosphorylated by the constitutively active type II receptor, once the two receptors are brought in contact with each other upon ligand binding. Huse et al. [4] have now determined the crystal structure of the unphosphorylated kinase domain of the TGFβ type I receptor in a complex with the 'FK606-binding protein' FKBP12. FKBP12 binds to the GS domain, protecting the phosphorylation sites and stabilizing the receptor in an inactive conformation, which is maintained by interactions between the GS domain and the amino-terminal lobe of the kinase. The relevance of FKBP12 binding to the type I receptor is controversial, but it was necessary for the structure determination.
The GS domain is tightly folded into two 180° turns in the space of seven residues, and is partially buried in the rest of the protein. Although the phosphorylated form of the receptor has not been examined structurally, it seems reasonable that phosphorylation of the GS domain would change its conformation and relieve its inhibitory effects on the receptor's kinase activity. The GS domain may not be required just to inactivate the kinase -it may also have an active role in stimulating the kinase. Evidence for this has come from the observation that deletions of the GS domain inactivate the receptor; this implies that a phosphorylated GS domain may be required in the active state [7] . Obviously, the structure of the activated form of the receptor will be of considerable interest.
Amino-acid sequence alignment has shown that, with regard to its kinase domain, the TGFβ receptor is most closely related to the insulin receptor tyrosine kinase and less related to other serine/threonine kinases. Not surprisingly, the α helices of the C lobe of the TGFβ type I receptor can be superimposed onto the equivalent helices of the insulin receptor, with a better fit than when they are superimposed upon protein kinase A, which contains a serine/threonine kinase domain. The catalytic region of the TGFβ type I receptor is thus more similar to tyrosine kinases than serine/threonine kinases. TGFβ receptors might be intermediates between tyrosine and serine threonine kinases.
An adaptor protein for Smads
The Smads were first identified by genetic analysis in the fruitfly Drosophila and nematode Caenorhabditis eleganstheir name derives from Mad (Drosophila) and sma (C. elegans), the first genes found to encode members of the family [3] . Subsequent cloning of vertebrate homologs of these genes led to discoveries about their function, particularly details of their biochemical properties [1] [2] [3] . The Smads were found to fall into distinct subtypes with different properties. Thus, the 'receptor-associated' Smads (R-Smads) complex with the type I receptors; they are phosphorylated by the receptor kinase on ligand activation, form a complex with a 'common' Smad (Co-Smad) and move into the nucleus (Figure 1 ). One question remaining from this skeletal view of TGFβ signaling is whether there are cytoplasmic anchors for the Smads. Now, in a very nice study, Tsukazaki et al. [5] have identified a protein dubbed 'Smad anchor for receptor activation', or SARA for short, which appears to be such an anchor.
SARA was isolated in a screen for proteins that interact with the carboxy-terminal, transcriptional activator (MH2) domain of Smad2. The SARA protein has a socalled 'FYVE' domain, which is a double zinc-finger domain that is found in several otherwise unrelated proteins. In some of these other proteins, the FYVE domain has been shown to bind phosphatidylinositol-3-phosphate (PI(3)P), and so it might mediate interactions between the protein that contains it and membranes [5] . It seems likely that the FYVE domain in SARA functions in this manner, but further experimentation will be required to confirm this hypothesis.
One obvious question is whether SARA really does act as a cytoplasmic anchor for the Smads. SARA was found to bind unphosphorylated Smad2, and to be released from this complex when Smad2 is phosphorylated by the type I receptor (the basal level of SARA phosphorylation remains unchanged on activation of the pathway). It appears that Smad2-Smad4 and Smad2-SARA complexes are mutually exclusive. Removing the Smad-binding domain of SARA did not significantly reduce its interaction with the receptor, showing that this is Smad-independent. SARA probably binds directly to Smads, as the bacterially expressed proteins were found to bind to each other efficiently. Phosphorylated forms of Smad were found not be bind efficiently to the SARA Smad-binding domain. Further, SARA was found to bind to TGFβ receptor complexes.
The model that emerges from these various observations is as follows (Figure 1 ). SARA is directed by its FYVE domain to the membrane, where TGFβ receptor molecules are located. At the membrane, SARA binds unphosphorylated Smad2, thereby concentrating this intermediary signaling molecule in the vicinity of TGFβ receptor molecules. The carboxyl terminus of SARA facilitates more direct interactions with TGFβ receptor complexes; on receptor activation following ligand binding, Smad2 is phosphorylated and released from the SARA adaptor protein, forming Smad2-Smad4 complexes that move from the cytoplasm to the nucleus to activate target genes.
How specific are SARA-Smad interactions? Interestingly, SARA was found to bind only to Smad2 or Smad3, and not to the other Smads. Previous studies have shown that pathways activated by different TGFβ family ligands use different Smads to send signals, raising the possibility that other pathways may use different SARA-like adaptor proteins. Searches of genome sequence databases have indeed provided evidence for the existence of other SARA-like proteins in humans, but whether they really function in the various TGFβ family signaling pathways remains to be seen. As SARA interacts with the Smads via its Smad-binding domain, and such domains are present in the related proteins, this does however seem a likely possibility.
Studies using HepG2 cells have shown that various mutant derivatives of SARA can suppress transcriptional induction
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Figure 1
A general model of the TGFβ signaling pathway. A ligand binds to the type I and type II receptor chains, resulting in phosphorylation of the GS domain of the type I receptor polypeptide. The membraneassociated protein SARA binds to an R-Smad and subsequently contacts the receptor, facilitating the R-Smad-receptor interaction. This interaction then causes the R-Smad to become phosphorylated and consequently released from SARA. The R-Smad then complexes with a Co-Smad and translocates to the nucleus. In the nucleus, the Smad complex interacts with a transcription cofactor and induces transcription downstream genes. 
Origin of signaling specificity
Recent studies of TGFβ signaling in C. elegans have also provided insights into receptor function and signaling specificity. Two distinct TGFβ-like signaling pathways, known as the 'Sma/Mab' and 'dauer' pathways, have been characterized in C. elegans [3] . The pathways were defined genetically: mutations of genes encoding different type I receptors were found to have phenotypic effects that were different subsets of the phenotype caused by mutations of daf-4, which encodes a type II receptor. The inference was that there are two pathways, each using a different type I receptor which interacts with distinct Smads and thereby activates different downstream targets [8] .
The genetic results thus indicate that, in C. elegans, distinct type I receptors confer specificity in TGFβ signaling. Is this a common theme for other TGFβ pathways in other organisms? The Drosophila type II receptor, Punt, has been found to interact with different type I receptors to mediate signaling by two TGFβ-family ligands, activin and Decapentaplegic [9, 10] . Previous biochemical studies in tissue culture have shown that different type I receptors can interact with a single type II receptor (Figure 2 ). These observations suggest that the ability of a given type II receptor to interact with multiple type receptors is an ancient property of TGFβ signaling.
Future issues
Crystal structures of the activated form of the TGFβ type I receptor and the receptor-SARA-Smad complex are likely to be important if we were are to understand this system at a deeper level, but such structures are likely to prove difficult to obtain. Such structures should provide important insights into TGFβ signaling and provide a foundation for drug design aimed at stimulating or inhibiting the pathway. Because the discovery of SARA is very recent, we know little about its importance in signaling and whether there are distinct SARA-like proteins for each receptor-Smad interaction. One also wonders whether there are additional proteins in the Smad-SARA complex -will SARA turn out to be part of a scaffolding complex?
Although there is more to be learned about the upstream aspects of TGFβ signaling, a lot of effort is being devoted to elucidating the interactions of TGFβ with other signaling pathways, as well as on downstream events in the nucleus. We have only a superficial view of what Smad gets up to in the nucleus. How do the Smads turn over, so as to turn off signaling after a suitable period of time? And with whom do they interact? How do other pathways intersect with TGFβ? There have been a number of reports of interactions between TGFβ and other signaling pathways: with the epidermal growth factor (EGF) and hepatocyte growth factor (HGF) pathways via Smad phosphorylation [11, 12] ; with the interferon γ pathway via induced transcription of the 'anti-Smad' Smad7 [13] ; and with the vitamin D pathway, as a result of Smad3 binding to and enhancing the transcriptional activity the vitamin D receptor [14] . Future studies of the TGFβ signaling pathways are bound to yield new surprises that integrate many important cellular pathways. 
